|
ZNF451 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.70603547850124E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.23090426740191E-11 |
| Normal-vs-Stage2 |
1.20840004669276E-09 |
| Normal-vs-Stage3 |
1.91735516352765E-12 |
| Normal-vs-Stage4 |
2.87281309852006E-12 |
| Stage1-vs-Stage2 |
7.378200E-01 |
| Stage1-vs-Stage3 |
7.501800E-02 |
| Stage1-vs-Stage4 |
1.154600E-01 |
| Stage2-vs-Stage3 |
3.765400E-01 |
| Stage2-vs-Stage4 |
3.472800E-01 |
| Stage3-vs-Stage4 |
8.327200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.92055268857894E-12 |
| Normal-vs-AfricanAmerican |
6.08329999999269E-05 |
| Normal-vs-Asian |
3.73140407461392E-11 |
| Caucasian-vs-AfricanAmerican |
1.413620E-01 |
| Caucasian-vs-Asian |
9.284800E-01 |
| AfricanAmerican-vs-Asian |
1.737180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.20534742981727E-12 |
| Normal-vs-Female |
2.36244357409987E-12 |
| Male-vs-Female |
9.815400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.40230066342428E-11 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
5.53446177775641E-13 |
| Normal-vs-Age(81-100Yrs) |
1.700060E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.747200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.100100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.965400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.650200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.310600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.193800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.277220E-03 |
| Classical-VS-Follicular |
5.446200E-01 |
| Classical-VS-Other |
4.450000E-01 |
| Classical-VS-Normal |
1.54619983483428E-10 |
| Tall-VS-Follicular |
2.058300E-02 |
| Tall-VS-Other |
4.897800E-01 |
| Tall-VS-Normal |
1.84408044390239E-12 |
| Follicular-VS-Other |
6.154400E-01 |
| Follicular-VS-Normal |
8.11473110928773E-12 |
| Other-VS-Normal |
9.411500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.2694290063564E-12 |
| Normal-vs-N1 |
2.26689778060063E-11 |
| N0-vs-N1 |
7.383400E-01 |
|
|
